

David G Mcfadden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1660747/publications.pdf>

Version: 2024-02-01

23
papers

2,057
citations

567281

15
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

3828
citing authors

#	ARTICLE	IF	CITATIONS
1	Heart and extra-embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1. <i>Nature Genetics</i> , 1998, 18, 266-270.	21.4	345
2	The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosage-dependent manner. <i>Development (Cambridge)</i> , 2005, 132, 189-201.	2.5	298
3	Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. <i>Cell</i> , 2014, 156, 1298-1311.	28.9	241
4	Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in H ^{1/4} rthle Cell Carcinoma. <i>Cancer Cell</i> , 2018, 34, 242-255.e5.	16.8	185
5	Mutational landscape of <i>EGFR</i> , <i>MYC</i> , and <i>Kras</i> driven genetically engineered mouse models of lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6409-E6417.	7.1	158
6	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
7	p53 constrains progression to anaplastic thyroid carcinoma in a <i>Braf</i> -mutant mouse model of papillary thyroid cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1600-9.	7.1	131
8	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	1.1	119
9	The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung. <i>Journal of Thoracic Oncology</i> , 2015, 10, 553-564.	1.1	100
10	Identification of Oncogenic Mutations and Gene Fusions in the Follicular Variant of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2457-E2462.	3.6	55
11	Heart development: learning from mistakes. <i>Current Opinion in Genetics and Development</i> , 2002, 12, 328-335.	3.3	43
12	Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. <i>Oncotarget</i> , 2014, 5, 3996-4010.	1.8	40
13	Misexpression of dHAND induces ectopic digits in the developing limb bud in the absence of direct DNA binding. <i>Development (Cambridge)</i> , 2002, 129, 3077-88.	2.5	40
14	Short Review: Genomic Alterations in H ^{1/4} rthle Cell Carcinoma. <i>Thyroid</i> , 2019, 29, 471-479.	4.5	39
15	Genetics, Diagnosis, and Management of H ^{1/4} rthle Cell Thyroid Neoplasms. <i>Frontiers in Endocrinology</i> , 2021, 12, 696386.	3.5	20
16	TK216 targets microtubules in Ewing sarcoma cells. <i>Cell Chemical Biology</i> , 2022, 29, 1325-1332.e4.	5.2	19
17	Engineering Forward Genetics into Cultured Cancer Cells for Chemical Target Identification. <i>Cell Chemical Biology</i> , 2019, 26, 1315-1321.e3.	5.2	16
18	Scinderin promotes fusion of electron transport chain dysfunctional muscle stem cells with myofibers. <i>Nature Aging</i> , 2022, 2, 155-169.	11.6	15

#	ARTICLE	IF	CITATIONS
19	Mitochondrial DNA Haplotypes as Genetic Modifiers of Cancer. Trends in Cancer, 2020, 6, 1044-1058.	7.4	14
20	Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: A pilot study.. Journal of Clinical Oncology, 2013, 31, 6025-6025.	1.6	11
21	A Multipronged Approach Establishes Covalent Modification of β -Tubulin as the Mode of Action of Benzamide Anti-cancer Toxins. Journal of Medicinal Chemistry, 2020, 63, 14054-14066.	6.4	9
22	Dabrafenib Induced Pancreatitis: A Rare Event During RAI- Refractory Treatment of Metastatic Papillary Thyroid Cancer. Journal of the Endocrine Society, 2021, 5, A888-A889.	0.2	1
23	Abstract GS3-09: Loss of <i>ASXL1</i> tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer. Cancer Research, 2022, 82, GS3-09-GS3-09.	0.9	1